Glyxambi is the original research product backed with Global Quality, Therapy defining legacy & Robust experience
Experience the journey of innovation with Glyxambi
Learn more about powerful HbA1c reduction.
Learn more about CV outcomes with Empagliflozin and Linagliptin
-
CV: Cardiovascular disease.
-
FDC: Fixed dose combination.
-
HbA1c: Glycated haemoglobin.
-
SGLT2i: Sodium-glucose co-transporter 2 inhibitor.
-
DPP4i: Dipeptidyl peptidase 4 inhibitor.
Disclaimer:
-
- Glyxambi is not indicated for BP or weight reduction.